Skip to content
Inciteful Med
Resources About us Ask a Question

Are African Americans at Higher Risk for Multiple Myeloma?

Published: | Updated:

African Americans are two to three times more likely to develop multiple myeloma and are often diagnosed younger. However, they frequently have favorable tumor biology. When given equal access to modern treatments and stem cell transplants, African American patients have excellent survival rates.

Key Takeaways

  • • African Americans have a two to three times higher risk of being diagnosed with multiple myeloma than white Americans.
  • • The precursor blood condition, MGUS, is significantly more common in people of African descent.
  • • African American patients often have standard-risk tumor biology, making their multiple myeloma highly treatable.
  • • Historical differences in survival rates are driven by socioeconomic barriers and unequal access to care, not the biology of the disease itself.
  • • With equal access to modern therapies and stem cell transplants, African American patients experience excellent outcomes and survival rates.

Yes, being African American does affect your risk of developing multiple myeloma, but it should not change the goal or quality of your treatment. African Americans are two to three times more likely to be diagnosed with multiple myeloma than white Americans [1][2][3]. However, research shows that when African American patients receive equal access to modern treatments and stem cell transplants, they have excellent responses and their survival rates are equal to, or even better than, other groups [4][5][6].

Understanding the Increased Risk

It is well-established that the incidence of multiple myeloma is significantly higher in the African American population [7][8]. African American patients are also frequently diagnosed at a younger age compared to other groups [9][10]. While the exact reasons for this higher risk are still being researched, the disease process often begins with a precursor condition called MGUS (Monoclonal Gammopathy of Undetermined Significance). MGUS is a non-cancerous condition where the body overproduces a specific protein, and it is more common in people of African descent [9].

Interestingly, while MGUS is more common, the yearly risk of it turning into active multiple myeloma is generally considered to be similar to other populations (historically cited as about 1% per year), though some recent studies suggest it could be slightly lower in African Americans [11]. Because of this ongoing risk, regular check-ups with a hematologist to monitor your blood are essential.

Favorable Tumor Biology

When doctors look at the genetics of the myeloma cells—known as tumor biology—the findings are generally encouraging for African American patients. It is important to know that these are “acquired” genetic changes that happen only in the cancer cells, not hereditary genes that run in your family or can be passed to your children.

The fundamental molecular makeup of the disease is very similar across different racial groups [12]. However, African American patients are actually more likely to have “standard-risk” genetic features inside their myeloma cells [5][3]. For example, the t(11;14) abnormality (a swapping of genetic material between chromosomes 11 and 14 inside the cancer cell) is more common and generally responds well to standard therapies. At the same time, African Americans have a lower rate of high-risk genetic mutations, such as del(17p), which is associated with more aggressive and harder-to-treat disease [13][10].

To find out your specific tumor biology, your doctor will perform a bone marrow biopsy and run a test called FISH (Fluorescence In Situ Hybridization). This favorable biology means the cancer is highly treatable when the right therapies are applied.

The Power of Equal Access to Treatment

Historically, broader national statistics have sometimes shown worse overall survival rates for African American patients with multiple myeloma [14][15]. Modern research has proven that these disparities are primarily driven by socioeconomic barriers, delays in care, and unequal access to standard healthcare, rather than the disease itself being more deadly [12][16].

When studies look at “equal access” healthcare settings—like the Veterans Affairs (VA) system—or closely monitored clinical trials, the survival gap disappears [17][18]. When African American patients are given timely access to modern novel therapies (such as targeted daily pills or IV immunotherapies given at a clinic) and autologous stem cell transplants (a procedure using a patient’s own healthy stem cells to help their bone marrow recover after high-dose chemotherapy), their outcomes are outstanding [19][6].

Additionally, because African Americans have historically been underrepresented in multiple myeloma clinical trials, participating in one can be a powerful way to access cutting-edge treatments. Advocating for yourself and ensuring you are evaluated at a specialized myeloma center that offers these modern, standard-of-care treatments is the most critical step you can take for your long-term health. Organizations like the International Myeloma Foundation or the Multiple Myeloma Research Foundation can help you locate a specialist.

Frequently Asked Questions

Are African Americans at a higher risk for multiple myeloma?
Yes, African Americans are two to three times more likely to be diagnosed with multiple myeloma compared to white Americans. They are also frequently diagnosed at a younger age, and the precursor condition called MGUS is more common in people of African descent.
Do African Americans have a more aggressive type of multiple myeloma?
No, research shows that African American patients are actually more likely to have standard-risk genetic features inside their myeloma cells. They have lower rates of high-risk mutations, making the disease highly treatable with standard therapies.
What is the multiple myeloma survival rate for African Americans?
When African American patients have equal access to modern treatments, clinical trials, and stem cell transplants, their survival rates are equal to or even better than other groups. Historical disparities in survival are primarily due to healthcare access barriers rather than the disease biology.
What is MGUS and how does it relate to multiple myeloma?
MGUS stands for Monoclonal Gammopathy of Undetermined Significance. It is a non-cancerous condition where the body overproduces a specific protein, and it can sometimes turn into multiple myeloma. It is more common in people of African descent and requires regular monitoring by a hematologist.
What are the standard treatments for multiple myeloma?
Effective treatments include targeted daily pills, intravenous immunotherapies, and autologous stem cell transplants. Being evaluated at a specialized myeloma center that offers these standard-of-care options is the most critical step for achieving the best possible outcome.

Questions for Your Doctor

  • • What specific genetic features did my FISH testing reveal, and do I have standard-risk markers like t(11;14) or high-risk markers like del(17p)?
  • • Am I being evaluated for an autologous stem cell transplant at a specialized center, and what is the timeline for that?
  • • Does my current treatment plan include modern therapies, such as targeted pills or IV immunotherapies, and are they the standard of care?
  • • Are there any clinical trials available that I would be a good candidate for, given my specific tumor biology?
  • • How often will we monitor my bloodwork and what specific markers are we tracking to ensure the treatment is working?

Questions for You

  • • What symptoms first brought me to the doctor, and how have they changed over time?
  • • Are there any barriers—like transportation, work schedules, or insurance coverage—that might make it difficult for me to access specialized care or a stem cell transplant?
  • • Have I considered seeking a second opinion from a dedicated multiple myeloma specialist to ensure I am getting the most up-to-date treatment plan?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma.

    Blue B, Pierre A, Mikhael J

    Clinical lymphoma, myeloma & leukemia 2023; (23(9)):651-659 doi:10.1016/j.clml.2023.05.005.

    PMID: 37290997
  2. 2

    African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities.

    Pierre A, Williams TH

    Clinical journal of oncology nursing 2020; (24(4)):439-443 doi:10.1188/20.CJON.439-443.

    PMID: 32678364
  3. 3

    Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry.

    Baughn LB, Pearce K, Larson D, et al.

    Blood cancer journal 2018; (8(10)):96 doi:10.1038/s41408-018-0132-1.

    PMID: 30305608
  4. 4

    Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study.

    Ononogbu O, Akindele O, Yazdanfard S, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(7)):407 doi:10.1007/s00520-024-08619-8.

    PMID: 38833106
  5. 5

    Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study.

    Fillmore NR, Cirstea D, Munjuluri A, et al.

    Blood advances 2021; (5(18)):3511-3514 doi:10.1182/bloodadvances.2020004001.

    PMID: 34428278
  6. 6

    Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.

    Ailawadhi S, Parikh K, Abouzaid S, et al.

    Blood advances 2019; (3(20)):2986-2994 doi:10.1182/bloodadvances.2019000308.

    PMID: 31648322
  7. 7

    Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations.

    Mikhael J, Bhutani M, Cole CE

    The American journal of medicine 2023; (136(1)):33-41 doi:10.1016/j.amjmed.2022.08.030.

    PMID: 36150517
  8. 8

    Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features.

    VanValkenburg ME, Pruitt GI, Brill IK, et al.

    Cancer causes & control : CCC 2016; (27(1)):81-91 doi:10.1007/s10552-015-0685-2.

    PMID: 26596855
  9. 9

    Monoclonal Gammopathies in Africa.

    Bolarinwa A, Odukoya L, Buadi F, et al.

    Clinical lymphoma, myeloma & leukemia 2025; (25(9)):e696-e703.e2 doi:10.1016/j.clml.2025.05.023.

    PMID: 40579286
  10. 10

    Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.

    Kazandjian D, Hill E, Hultcrantz M, et al.

    Blood cancer journal 2019; (9(2)):15 doi:10.1038/s41408-019-0177-9.

    PMID: 30718460
  11. 11

    Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.

    Dhodapkar MV, Sexton R, Hoering A, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(22)):5814-5819 doi:10.1158/1078-0432.CCR-20-2119.

    PMID: 32816893
  12. 12

    How researchers are addressing the racial imbalance in multiple myeloma.

    Willyard C

    Nature 2020; (587(7835)):S64-S65 doi:10.1038/d41586-020-03228-x.

    PMID: 33239806
  13. 13

    Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.

    Kanapuru B, Fernandes LL, Fashoyin-Aje LA, et al.

    Blood advances 2022; (6(6)):1684-1691 doi:10.1182/bloodadvances.2021005482.

    PMID: 35114691
  14. 14

    Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare.

    Zhou J, Sweiss K, Nutescu EA, et al.

    JCO oncology practice 2021; (17(3)):e294-e312 doi:10.1200/OP.20.00479.

    PMID: 33449809
  15. 15

    Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.

    Ailawadhi S, Frank RD, Sharma M, et al.

    Cancer 2018; (124(8)):1710-1721 doi:10.1002/cncr.31237.

    PMID: 29360160
  16. 16

    Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.

    Ailawadhi S, Jagannath S, Lee HC, et al.

    Cancer 2020; (126(19)):4332-4340 doi:10.1002/cncr.33089.

    PMID: 32706404
  17. 17

    Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer.

    Kotha NV, Kumar A, Qiao EM, et al.

    Journal of the National Cancer Institute 2022; (114(4)):600-608 doi:10.1093/jnci/djab219.

    PMID: 34918091
  18. 18

    The histopathology of myeloma in the bone marrow.

    Fujino M

    Journal of clinical and experimental hematopathology : JCEH 2018; (58(2)):61-67 doi:10.3960/jslrt.18014.

    PMID: 29998977
  19. 19

    Do Patients With Multiple Myeloma Enrolled in Clinical Trials Live Longer?

    Aung TN, Bickell NA, Jagannath S, et al.

    American journal of clinical oncology 2021; (44(12)):603-612 doi:10.1097/COC.0000000000000873.

    PMID: 34753885

This information about multiple myeloma risk and treatment is for educational purposes only and does not replace professional medical advice. Always consult your hematologist or oncologist regarding your specific diagnosis, genetic testing, and treatment plan.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.